EGFR associated expression profiles vary with breast tumor subtype

BMC Genomics

Volumn 8, Issue , 2007, Pages

  Hoadley, Katherine A ^a,b   Weigman, Victor J ^a,b   Fan, Cheng ^a,b   Sawyer, Lynda R ^a   He, Xiaping ^a,b   Troester, Melissa A ^c   Sartor, Carolyn I ^a,b   Rieger House, Thais ^d   Bernard, Philip S ^d   Carey, Lisa A ^a   Perou, Charles M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARBOPLATIN; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; FLUOROURACIL; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAS PROTEIN; U 1026; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PREDICTION; PROGNOSIS; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; MAP KINASE KINASE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 35248889408     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-8-258     Document Type: Article

References (83)

1. Yarden Y Sliwkowski MX Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2001, 2:127-137 10.1038/35052073 11252954
2. Sørlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen MB van de Rijn M Jeffrey SS Thorsen T Quist H Matese JC Brown PO Botstein D Eystein Lonning P Borresen-Dale AL Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 2001, 98:10869-10874 58566 11553815 10.1073/pnas.191367098
3. Sørlie T Tibshirani R Parker J Hastie T Marron JS Nobel A Deng S Johnsen H Pesich R Geisler S Demeter J Perou CM Lonning PE Brown PO Borresen-Dale AL Botstein D Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 2003, 100:8418-8423 166244 12829800 10.1073/pnas.0932692100
4. Perou CM Sørlie T Eisen MB van de Rijn M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA Fluge O Pergamenschikov A Williams C Zhu SX Lonning PE Borresen-Dale AL Brown PO Botstein D Molecular portraits of human breast tumours Nature 2000, 406:747-752 10.1038/35021093 10963602
5. Hu Z Troester M Perou CM High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays Biotechniques 2005, 38:121-124 15679094
6. Nielsen TO Hsu FD Jensen K Cheang M Karaca G Hu Z Hernandez-Boussard T Livasy C Cowan D Dressler L Akslen LA Ragaz J Gown AM Gilks CB van De Rijn M Perou CM Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 2004, 10:5367-5374 10.1158/1078-0432.CCR-04-0220 15328174
7. Salomon DS Brandt R Ciardiello F Normanno N Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 1995, 19:183-232 10.1016/1040-8428(94)00144-I 7612182
8. Mass RD The HER receptor family: A rich target for therapeutic development Int J Radiat Oncol Biol Phys 2004, 58:932-940 10.1016/ j.ijrobp.2003.09.093 14967453
9. Baselga J Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 2002, 7 Suppl 4:2-8 10.1634/ theoncologist.7-suppl_4-2 12202782
10. Culy CR Faulds D Gefitinib Drugs 2002, 62:2237-48; discussion 2249-50 10.2165/00003495-200262150-00008 12381224
11. Graham J Muhsin M Kirkpatrick P Cetuximab Nat Rev Drug Discov 2004, 3:549-550 10.1038/nrd1287 15272498
12. Dowell J Minna JD Kirkpatrick P Erlotinib hydrochloride Nat Rev Drug Discov 2005, 4:13-14 10.1038/nrd1612 15690599
13. Tamura K Fukuoka M Molecular target-based cancer therapy: Tyrosine kinase inhibitors Int J Clin Oncol 2003, 8:207-211 10.1007/ s10147-003-0320-1 12955575
14. Ciardiello F Caputo R Bianco R Damiano V Pomatico G De Placido S Bianco AR Tortora G Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 2000, 6:2053-2063 10815932
15. She QB Solit D Basso A Moasser MM Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling Clin Cancer Res 2003, 9:4340-4346 14555504
16. Moasser MM Basso A Averbuch SD Rosen N The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res 2001, 61:7184-7188 11585753
17. Bianco R Shin I Ritter CA Yakes FM Basso A Rosen N Tsurutani J Dennis PA Mills GB Arteaga CL Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 2003, 22:2812-2822 10.1038/sj.onc.1206388 12743604
18. Lev DC Kim LS Melnikova V Ruiz M Ananthaswamy HN Price JE Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells Br J Cancer 2004, 91:795-802 15280923
19. Normanno N De Luca A Maiello MR Campiglio M Napolitano M Mancino M Carotenuto A Viglietto G Menard S The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib J Cell Physiol 2006, 207:420-427 10.1002/jcp.20588 16419029
20. Janmaat ML Rodriguez JA Gallegos-Ruiz M Kruyt FA Giaccone G Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells Int J Cancer 2006, 118:209-214 10.1002/ijc.21290 16003751
21. Moyano JV Evans JR Chen F Lu M Werner ME Yehiely F Diaz LK Turbin D Karaca G Wiley E Nielsen TO Perou CM Cryns VL AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer J Clin Invest 2006, 116:261-270 1323258 16395408 10.1172/JCI25888
22. Troester MA Hoadley KA Sorlie T Herbert BS Borresen-Dale AL Lonning PE Shay JW Kaufmann WK Perou CM Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer Cancer Res 2004, 64:4218-4226 10.1158/ 0008-5472.CAN-04-0107 15205334
23. Troester MA Hoadley KA Parker JS Perou CM Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines Environ Health Perspect 2004, 112:1607-1613 1247657 15598611
24. Sartor CI Dziubinski ML Yu CL Jove R Ethier SP Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells Cancer Res 1997, 57:978-987 9041204
25. Bertucci F Finetti P Rougemont J Charafe-Jauffret E Cervera N Tarpin C Nguyen C Xerri L Houlgatte R Jacquemier J Viens P Birnbaum D Gene expression profiling identifies molecular subtypes of inflammatory breast cancer Cancer Res 2005, 65:2170-2178 10.1158/ 0008-5472.CAN-04-4115 15781628
26. Chou TC Talalay P Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984, 22:27-55 10.1016/0065-2571(84)90007-4 6382953
27. Schraml P Bucher C Bissig H Nocito A Haas P Wilber K Seelig S Kononen J Mihatsch MJ Dirnhofer S Sauter G Cyclin E overexpression and amplification in human tumours J Pathol 2003, 200:375-382 10.1002/ path.1356 12845634
28. Sieuwerts AM Look MP Meijer-van Gelder ME Timmermans M Trapman AM Garcia RR Arnold M Goedheer AJ de Weerd V Portengen H Klijn JG Foekens JA Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients Clin Cancer Res 2006 12 3319 3328 10.1158/1078-0432.CCR-06-0225 16740753
29. Foulkes WD Brunet JS Stefansson IM Straume O Chappuis PO Begin LR Hamel N Goffin JR Wong N Trudel M Kapusta L Porter P Akslen LA The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 2004, 64:830-835 10.1158/0008-5472.CAN-03-2970 14871808
30. Navolanic PM Steelman LS McCubrey JA EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review) Int J Oncol 2003, 22:237-252 12527919
31. Medema RH Kops GJ Bos JL Burgering BM AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 Nature 2000, 404:782-787 10.1038/35008115 10783894
32. Delmas C Manenti S Boudjelal A Peyssonnaux C Eychene A Darbon JM The p42/ p44 mitogen-activated protein kinase activation triggers p27Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells J Biol Chem 2001, 276:34958-34965 10.1074/jbc.M101714200 11418594
33. van de Vijver MJ He YD van't Veer LJ Dai H Hart AA Voskuil DW Schreiber GJ Peterse JL Roberts C Marton MJ Parrish M Atsma D Witteveen A Glas A Delahaye L van der Velde T Bartelink H Rodenhuis S Rutgers ET Friend SH Bernards R A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002, 347:1999-2009 10.1056/NEJMoa021967 12490681
34. Chang HY Nuyten DS Sneddon JB Hastie T Tibshirani R Sorlie T Dai H He YD van't Veer LJ Bartelink H van de Rijn M Brown PO van de Vijver MJ Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci U S A 2005, 102:3738-3743 548329 15701700 10.1073/pnas.0409462102
35. Herschkowitz JI Simin K Weigman VJ Mikaelian I Usary J Hu Z Rasmussen KE Jones LP Assefnia S Chandrasekharan S Backlund MG Yin Y Khramtsov AI Bastein R Quackenbush J Glazer RI Brown PH Green JE Kopelovich L Furth PA Palazzo JP Olopade OI Bernard PS Churchill GA Van Dyke T Perou CM Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors Genome Biol 2007, 8:R76 1929138 17493263 10.1186/gb-2007-8-5-r76
36. Normanno N De Luca A Maiello MR Mancino M D'Antonio A Macaluso M Caponigro F Giordano A Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: Current status and future development Front Biosci 2005, 10:2611-2617 10.2741/1725 15970523
37. Agrawal A Gutteridge E Gee JM Nicholson RI Robertson JF Overview of tyrosine kinase inhibitors in clinical breast cancer Endocr Relat Cancer 2005, 12 Suppl 1:S135-44 10.1677/erc.1.01059 16113090
38. Singh AB Harris RC Autocrine, paracrine and juxtacrine signaling by EGFR ligands Cell Signal 2005, 17:1183-1193 10.1016/j.cellsig.2005.03.026 15982853
39. Arnes JB Brunet JS Stefansson I Begin LR Wong N Chappuis PO Akslen LA Foulkes WD Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer Clin Cancer Res 2005, 11:4003-4011 10.1158/ 1078-0432.CCR-04-2064 15930334
40. Foulkes WD Stefansson IM Chappuis PO Begin LR Goffin JR Wong N Trudel M Akslen LA Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 2003, 95:1482-1485 14519755
41. Elstrodt F Hollestelle A Nagel JH Gorin M Wasielewski M van den Ouweland A Merajver SD Ethier SP Schutte M BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants Cancer Res 2006, 66:41-45 10.1158/0008-5472.CAN-05-2853 16397213
42. Zhou C Huang P Liu J The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells Biochem Biophys Res Commun 2005, 336:952-960 10.1016/j.bbrc.2005.08.197 16165098
43. Bhattacharyya A Ear US Koller BH Weichselbaum RR Bishop DK The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin J Biol Chem 2000, 275:23899-23903 10.1074/jbc.C000276200 10843985
44. Husain A He G Venkatraman ES Spriggs DR BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II) Cancer Res 1998, 58:1120-1123 9515792
45. Tassone P Tagliaferri P Perricelli A Blotta S Quaresima B Martelli ML Goel A Barbieri V Costanzo F Boland CR Venuta S BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells Br J Cancer 2003, 88:1285-1291 10.1038/sj.bjc.6600859 12698198
46. Quinn JE Kennedy RD Mullan PB Gilmore PM Carty M Johnston PG Harkin DP BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 2003, 63:6221-6228 14559807
47. Kennedy RD Quinn JE Mullan PB Johnston PG Harkin DP The role of BRCA1 in the cellular response to chemotherapy J Natl Cancer Inst 2004, 96:1659-1668 15547178
48. Morelli MP Cascone T Troiani T De Vita F Orditura M Laus G Eckhardt SG Pepe S Tortora G Ciardiello F Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors Ann Oncol 2005, 16 Suppl 4:iV61-iv68 10.1093/annonc/mdi910 15923432
49. Hambek M Baghi M Strebhardt K Baumann H Gstottner W Knecht R Reduction of cisplatin dosage by ZD 1839 Anticancer Res 2005, 25:3985-3988 16309188
50. Cetuximab Alone and Cetuximab With Carboplatin in ER/PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer http://www.clinicaltrials.gov/ ct/show/NCT00232505
51. Cytoscape http://www.cytoscape.org
52. Shannon P Markiel A Ozier O Baliga NS Wang JT Ramage D Amin N Schwikowski B Ideker T Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks Genome Res 2003, 13:2498-2504 403769 14597658 10.1101/gr.1239303
53. Gutierrez MC Detre S Johnston S Mohsin SK Shou J Allred DC Schiff R Osborne CK Dowsett M Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase J Clin Oncol 2005, 23:2469-2476 10.1200/ JCO.2005.01.172 15753463
54. Arpino G Green SJ Allred DC Lew D Martino S Osborne CK Elledge RM HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study Clin Cancer Res 2004, 10:5670-5676 10.1158/1078-0432.CCR-04-0110 15355892
55. Britton DJ Hutcheson IR Knowlden JM Barrow D Giles M McClelland RA Gee JM Nicholson RI Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth Breast Cancer Res Treat 2006, 96:131-146 10.1007/s10549-005-9070-2 16261397
56. Ellis MJ Tao Y Young O White S Proia AD Murray J Renshaw L Faratian D Thomas J Dowsett M Krause A Evans DB Miller WR Dixon JM Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole J Clin Oncol 2006, 24:3019-3025 10.1200/JCO.2005.04.3034 16754938
57. Dowsett M Houghton J Iden C Salter J Farndon J A'Hern R Sainsbury R Baum M Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status Ann Oncol 2006, 17:818-826 10.1093/annonc/ mdl016 16497822
58. Shou J Massarweh S Osborne CK Wakeling AE Ali S Weiss H Schiff R Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 2004, 96:926-935 15199112
59. Ciardiello F Troiani T Caputo F De Laurentiis M Tortora G Palmieri G De Vita F Diadema MR Orditura M Colantuoni G Gridelli C Catalano G De Placido S Bianco AR Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer Br J Cancer 2006, 94:1604-1609 16685276
60. Polychronis A Sinnett HD Hadjiminas D Singhal H Mansi JL Shivapatham D Shousha S Jiang J Peston D Barrett N Vigushin D Morrison K Beresford E Ali S Slade MJ Coombes RC Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial Lancet Oncol 2005, 6:383-391 10.1016/S1470-2045(05)70176-5 15925816
61. Tokunaga E Kimura Y Oki E Ueda N Futatsugi M Mashino K Yamamoto M Ikebe M Kakeji Y Baba H Maehara Y Akt is frequently activated in HER2/ neu-positive breast cancers and associated with poor prognosis among hormone-treated patients Int J Cancer 2006, 118:284-289 10.1002/ ijc.21358 16049961
62. Zhou X Tan M Stone Hawthorne V Klos KS Lan KH Yang Y Yang W Smith TL Shi D Yu D Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers Clin Cancer Res 2004, 10:6779-6788 10.1158/1078-0432.CCR-04-0112 15501954
63. Kamradt MC Chen F Cryns VL The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation J Biol Chem 2001, 276:16059-16063 10.1074/jbc.C100107200 11274139
64. Kamradt MC Lu M Werner ME Kwan T Chen F Strohecker A Oshita S Wilkinson JC Yu C Oliver PG Duckett CS Buchsbaum DJ LoBuglio AF Jordan VC Cryns VL The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3 J Biol Chem 2005, 280:11059-11066 10.1074/jbc.M413382200 15653686
65. Liu ML Shibata MA Von Lintig FC Wang W Cassenaer S Boss GR Green JE Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice Oncogene 2001, 20:2044-2049 10.1038/sj.onc.1204280 11360188
66. von Minckwitz G Jonat W Fasching P du Bois A Kleeberg U Luck HJ Kettner E Hilfrich J Eiermann W Torode J Schneeweiss A A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 2005, 89:165-172 10.1007/ s10549-004-1720-2 15692759
67. Gasparini G Sarmiento R Amici S Longo R Gattuso D Zancan M Gion M Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: A phase I study with biological correlate Ann Oncol 2005, 16:1867-1873 10.1093/annonc/mdi393 16107496
68. Fountzilas G Pectasides D Kalogera-Fountzila A Skarlos D Kalofonos HP Papadimitriou C Bafaloukos D Lambropoulos S Papadopoulos S Kourea H Markopoulos C Linardou H Mavroudis D Briasoulis E Pavlidis N Razis E Kosmidis P Gogas H Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group Breast Cancer Res Treat 2005, 92:1-9 10.1007/ s10549-005-0322-y 15980985
69. Asterand: Human breast cancer cell lines http://www.asterand.com/ Asterand/BIOREPOSITORY/hbreastcancercelllines.aspx
70. Tissue Culture Facility at the University of North Carolina at Chapel Hill http://www.unc.edu/depts/tcf/info.html
71. Hu Z Fan C Oh DS Marron JS He X Qaqish BF Livasy C Carey LA Reynolds E Dressler L Nobel A Parker J Ewend MG Sawyer LR Wu J Liu Y Nanda R Tretiakova M Ruiz Orrico A Dreher D Palazzo JP Perreard L Nelson E Mone M Hansen H Mullins M Quackenbush JF Ellis MJ Olopade OI Bernard PS Perou CM The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 2006, 7:96 1468408 16643655 10.1186/ 1471-2164-7-96
72. Oh DS Troester MA Usary J Hu Z He X Fan C Wu J Carey LA Perou CM Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers J Clin Oncol 2006, 24:1656-1664 10.1200/JCO.2005.03.2755 16505416
73. Weigelt B Hu Z He X Livasy C Carey LA Ewend MG Glas AM Perou CM Van't Veer LJ Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer Cancer Res 2005, 65:9155-9158 10.1158/0008-5472.CAN-05-2553 16230372
74. Perreard L Fan C Quackenbush JF Mullins M Gauthier NP Nelson E Mone M Hansen H Buys SS Rasmussen K Orrico AR Dreher D Walters R Parker J Hu Z He X Palazzo JP Olopade OI Szabo A Perou CM Bernard PS Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay Breast Cancer Res 2006, 8:R23 1557722 16626501 10.1186/bcr1399
75. UNC Microarray Database https://genome.unc.edu/cgi-bin/SMD/publication/ viewPublication.pl?pub_no=62
76. Eisen MB Spellman PT Brown PO Botstein D Cluster analysis and display of genome-wide expression patterns Proc Natl Acad Sci U S A 1998, 95:14863-14868 24541 9843981 10.1073/pnas.95.25.14863
77. Eisen MB Brown PO DNA arrays for analysis of gene expression Methods Enzymol 1999, 303:179-205 10349646
78. Tusher V Tibshirani R Chu G Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-5121 33173 11309499 10.1073/pnas.091062498
79. Hosack DA Dennis G Jr. Sherman BT Lane HC Lempicki RA Identifying biological themes within lists of genes with EASE Genome Biol 2003, 4:R70 328459 14519205 10.1186/gb-2003-4-10-r70
80. KEGG: Kyoto Encyclopedia of Genes and Genomes http://www.genome.ad.jp/ kegg/
81. Ogata H Goto S Sato K Fujibuchi W Bono H Kanehisa M KEGG: Kyoto Encyclopedia of Genes and Genomes Nucleic Acids Res 1999, 27:29-34 148090 9847135 10.1093/nar/27.1.29
82. BioCarta http://www.biocarta.com
83. Fan C Oh DS Wessels L Weigelt B Nuyten DS Nobel AB van't Veer LJ Perou CM Concordance among gene-expression-based predictors for breast cancer N Engl J Med 2006, 355:560-569 10.1056/NEJMoa052933 16899776